Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA4 | P22748 | 1/20 | 0.54 |
| ▸ | CA6 | P23280 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | TPMT | P51580 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | TTR | P02766 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7466606 | 0.88 | CA12 (0.54) | CA12CA1CA2CA4CA6 | |
| SCHEMBL7614930 | 0.87 | ALDH1A1 (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL23998040 | 0.81 | TSHR (0.52) | TSHRLMNARAB9AMRGPRX4TTR | |
| Alkyrom SCHEMBL11412605 | 0.80 | ALDH1A1 (0.52) | TSHRMRGPRX4POLBALDH1A1MEN1 | |
| SCHEMBL16554589 | 0.78 | CA12 (0.65) | CA12CA1CA2CA4CA6 | |
| SCHEMBL7618833 | 0.77 | HCAR3 (0.47) | TSHRALDH1A1MEN1KMT2AHCAR3 | |
| SCHEMBL7466481 | 0.77 | TSHR (0.40) | CA12CA1CA2CA4CA6 | |
| SCHEMBL7470900 | 0.75 | ALDH1A1 (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7507805 | 0.75 | RXRA (0.43) | CA12CA1CA2CA4CA6 | |
| SCHEMBL8169400 | 0.74 | TP53 (0.49) | TSHRALDH1A1HCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090092553-A1 | MONOCARBOXYLATE TRANSPORTERS EXPRESSED IN CANCER CELLS | XENOPORT,INC. (US) | 2009-04-09 | — | — | US | claimed |
| EP-1651963-A4 | MONOCARBOXYLATE TRANSPORTERS EXPRESSED IN CANCER CELLS | XENOPORT INC (US) | 2007-03-21 | — | — | EP | claimed |
| EP-1651963-A2 | MONOCARBOXYLATE TRANSPORTERS EXPRESSED IN CANCER CELLS | Xenoport, Inc. (US) | 2006-05-03 | — | — | EP | claimed |
| WO-2005098444-A2 | MONOCARBOXYLATE TRANSPORTERS EXPRESSED IN CANCER CELLS | XENOPORT, INC. (US) | 2005-10-20 | — | — | WO | claimed |
| US-20050032135-A1 | Monocarboxylate transporters expressed in cancer cells | XENOPORT, INC. (US) | 2005-02-10 | — | — | US | claimed |
| US-20090092553-A1 | MONOCARBOXYLATE TRANSPORTERS EXPRESSED IN CANCER CELLS | XENOPORT,INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090092553-A1 | MONOCARBOXYLATE TRANSPORTERS EXPRESSED IN CANCER CELLS | XENOPORT,INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090092553-A1 | MONOCARBOXYLATE TRANSPORTERS EXPRESSED IN CANCER CELLS | XENOPORT,INC. (US) | 2009-04-09 | — | — | US | disclosed |
| EP-1651963-A4 | MONOCARBOXYLATE TRANSPORTERS EXPRESSED IN CANCER CELLS | XENOPORT INC (US) | 2007-03-21 | — | — | EP | disclosed |
| EP-1651963-A2 | MONOCARBOXYLATE TRANSPORTERS EXPRESSED IN CANCER CELLS | Xenoport, Inc. (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005098444-A2 | MONOCARBOXYLATE TRANSPORTERS EXPRESSED IN CANCER CELLS | XENOPORT, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| US-20050032135-A1 | Monocarboxylate transporters expressed in cancer cells | XENOPORT, INC. (US) | 2005-02-10 | — | — | US | disclosed |
| US-6433199-B1 | ANTITUMOR, ANTICANCER AGENTS | SHIONOGI BIORESEARCH CORPORATION | 2002-08-13 | — | — | US | disclosed |
| US-5969133-A | Bioreductive cytotoxic agents | SHIONGI BIORESEARCH CORP. (US) | 1999-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032135-A1 | Monocarboxylate transporters expressed in cancer cells | SLC16A1, SLC16A3, SLC16A8 | CA12 211/4885CA1 245/4885CA2 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.